Results 71 to 80 of about 415,720 (292)

Predicting human disease mutations and identifying drug targets from mouse gene knockout phenotyping campaigns

Disease Models & Mechanisms, 2019
Two large-scale mouse gene knockout phenotyping campaigns have provided extensive data on the functions of thousands of mammalian genes. The ongoing International Mouse Phenotyping Consortium (IMPC), with the goal of examining all ∼20,000 mouse genes ...
Robert Brommage, David R. Powell, Peter Vogel   +2 more
doaj   +1 more source

Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model

Molecular Oncology, EarlyView.
Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells
Daniel J. Smit, Thais Pereira‐Veiga, Helena Brauer, Michael Horn, Paula Nissen, Thomas Mair, Bente Siebels, Hannah Voß, Ruimeng Zhuang, Marie‐Therese Haider, Desiree Loreth, Margarita Iskhakova, Bele Lindemann, Julian Kött, Laure Cayrefourcq, Jasmin Wellbrock, Hartmut Schlüter, Klaus Pantel, Catherine Alix‐Panabières, Manfred Jücker   +19 more
wiley   +1 more source

Genome wide conditional mouse knockout resources

Drug Discovery Today: Disease Models, 2016
The International Knockout Mouse Consortium (IKMC) developed high throughput gene trapping and gene targeting pipelines that produced mostly conditional mutations of more than 18,500 genes in C57BL/6N mouse embryonic stem (ES) cells which have been archived and are freely available to the research community as a frozen resource. From this unprecedented
Marie-Christine Birling, Colin Fletcher, P. Ruiz Noppinger, Gautier Koscielny, Colin McKerlie, M. Hrabé de Angelis, Brendan Doe, William C. Skarnes, Richard H. Finnell, Stephen A. Murray, Martin Ringwald, Anthony P. West, Janet Rossant, Hilary Gates, Allan Bradley, Claudia Seisenberger, Edward Ryder, Kevin C K Lloyd, Paul N. Schofield, David M. Valenzuela, Barry Rosen, Barry Rosen, Francis S. Collins, J.T. Eppig, Vivek Iyer, G. P. Tocchini Valentini, P. J. de Jong, Paul Flicek, Geoff Hicks, Martin Fray, Terry Meehan, Alessia Gambadoro, Jens Hansen, Roland H. Friedel, Mohammed Selloum, Richard Baldock, Andras Nagy, Nadia Rosenthal, A. Pombero, Ralf Kühn, Cornelia Kaloff, S. Martínez, Susan Marschall, Yann Herault, Yann Herault, Yann Herault, P. Liu, A. F. Stewart, Elizabeth M. Simpson, Konstantinos Anastassiadis, Lydia Teboul, Joel Schick, Wolfgang Wurst, Haydn M. Prosser, Abdel Ayadi, R. G. Lopez, Mark W. Moore, Steve D.M. Brown, Frank Schnütgen, Andreas Hörlein, Lauryl M. J. Nutter, J. Beig, Guillaume Pavlovic, Guillaume Pavlovic, Guillaume Pavlovic, Damian Smedley, Antje Bürger, Ramiro Ramirez-Solis, Wendy Bushell, Francesco Chiani, H. von Melchner   +70 more
openaire   +7 more sources

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

Molecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen, Chung‐Teng Wang, Jia‐Ming Chang, Ai‐Li Shiau, Gia‐Shing Shieh, Yau‐Lin Tseng, Yi‐Ting Yen, Tang‐Hsiu Huang, Li‐Hsin Cheng, Yu‐Chih Wu, Chao‐Liang Wu, Bing‐Hua Su, Pensee Wu   +12 more
wiley   +1 more source

Robust and Sensitive Analysis of Mouse Knockout Phenotypes

PLoS ONE, 2012
A significant challenge of in-vivo studies is the identification of phenotypes with a method that is robust and reliable. The challenge arises from practical issues that lead to experimental designs which are not ideal. Breeding issues, particularly in the presence of fertility or fecundity problems, frequently lead to data being collected in multiple ...
Richard Mott, Natasha A. Karp, David Melvin, Sanger Mouse Genetics   +3 more
openaire   +4 more sources

Does Porphyromonas gingivalis truly inhibit the oral carcinogenesis?

Molecular Oncology, EarlyView.
 
Chen‐xi Li, Zhong‐cheng Gong
wiley   +1 more source

Mint3 is dispensable for pancreatic and kidney functions in mice

Biochemistry and Biophysics Reports, 2020
Munc-18 interacting protein 3 (Mint3) is an activator of hypoxia-inducible factor-1 in cancer cells, macrophages, and cancer-associated fibroblasts under pathological conditions. However, exactly which cells highly express Mint3 in vivo and whether Mint3
Yoohwa Chung, Yurika Saitoh, Tetsuro Hayashi, Yuya Fukui, Nobuo Terada, Motoharu Seiki, Yoshinori Murakami, Takeharu Sakamoto   +7 more
doaj  

Loss of proton‐sensing GPR4 reduces tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
G protein‐coupled receptor 4 (GPR4) is a pH‐sensing receptor activated by acidic pH. GPR4 expression is increased in patients with inflammatory bowel disease who are at high risk of developing colorectal cancer. In mouse models, loss of GPR4 attenuated tumor progression. This correlated with increased IL2 and natural killer cell activity.
Leonie Perren, Moana Busch, Pedro A. Ruiz, Ermanno Malagola, Valeria Baumeler, Federica Foti, Adelina Gross, Tobias Grütter, Hendrik Edel, Cordelia Schuler, Kristina Handler, Glenn De Lange, Isabelle C. Arnold, Cheryl de Vallière, Klaus Seuwen, Martin Hausmann, Gerhard Rogler   +16 more
wiley   +1 more source

Dose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment

Molecular Oncology, EarlyView.
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop, Edgar Cardenas De La Hoz, Hanne Verswyvel, Joey De Backer, Ho Wa Lau, Angela Privat‐Maldonado, Wim Vanden Berghe, Steve Vanlanduit, Evelien Smits, Annemie Bogaerts, Abraham Lin   +10 more
wiley   +1 more source

Antagonism of the Thromboxane‐Prostanoid Receptor as a Potential Therapy for Cardiomyopathy of Muscular Dystrophy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background Muscular dystrophy (MD) causes a progressive cardiomyopathy characterized by diffuse fibrosis, arrhythmia, heart failure, and early death. Activation of the thromboxane‐prostanoid receptor (TPr) increases calcium transients in cardiomyocytes ...
James D. West, Cristi L. Galindo, Kyungsoo Kim, John Jonghyun Shin, James B. Atkinson, Ines Macias‐Perez, Leo Pavliv, Bjorn C. Knollmann, Jonathan H. Soslow, Larry W. Markham, Erica J. Carrier   +10 more
doaj   +1 more source